Particle Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Proton therapy, Heavy-ion therapy), By System (Multi-room systems, Single-room systems), By Application (Treatment application, Research application), By Cancer-type (Pediatric Cancer, Lung Cancer, Breast cancer, Other cancers), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 999.21 Million
CAGR (2026-2031)	5.31%
Fastest Growing Segment	Breast Cancer
Largest Market	North America
Market Size (2031)	USD 1362.93 Million

Market Overview

The Global Particle Therapy Market will grow from USD 999.21 Million in 2025 to USD 1362.93 Million by 2031 at a 5.31% CAGR. Particle therapy is a specialized form of external beam radiotherapy that employs charged particles, such as protons and heavy ions, to irradiate malignancies with high precision by depositing maximum energy at the Bragg peak. The global market is primarily driven by the increasing incidence of cancer and the clinical necessity to minimize radiation toxicity in sensitive anatomical regions, which elevates the demand for this modality over traditional photon-based treatments. Furthermore, the continuous accumulation of clinical evidence supporting superior patient outcomes in pediatric and complex adult cases actively supports the broader adoption of these therapeutic systems.

However, the expansion of this sector is significantly challenged by the prohibitive capital investment required for facility construction and maintenance, alongside inconsistent insurance reimbursement policies which can hinder patient access. These financial barriers often restrict operational scalability, particularly in cost-sensitive healthcare environments. Illustrating the sustained demand within established markets despite these hurdles, according to the National Association for Proton Therapy, in 2024, a total of 18,202 patients received proton therapy treatment across the United States.

Key Market Drivers

The rising global prevalence of cancer and oncological disorders acts as a fundamental catalyst for the Global Particle Therapy Market, necessitating precise radiotherapeutic interventions. As malignancy rates increase, healthcare providers are compelled to adopt advanced modalities like proton therapy that maximize tumor control while minimizing off-target radiation to critical organs. This demand is particularly acute for complex cases where conventional photon therapy poses significant risks of long-term toxicity. Illustrating this escalating burden, according to the International Agency for Research on Cancer (IARC), February 2024, in the 'Global Cancer Burden' press release, it is predicted that new cancer cases globally will rise to over 35 million by 2050, a 77% increase from 2022 levels.

Simultaneously, technological advancements in compact and single-room proton therapy systems are revolutionizing accessibility by lowering capital barriers for medical institutions. The sector is shifting from massive multi-room facilities toward modular, smaller-footprint solutions that allow hospitals to integrate particle therapy into existing infrastructures with reduced financial risk. This transition toward cost-efficient technology is evidenced by commercial traction; according to Mevion Medical Systems, September 2024, in a press release, their compact proton therapy solutions captured 60% of the announced United States market over the past five years. Highlighting the critical necessity for such scalable innovations, according to the American Cancer Society, January 2024, in the 'Cancer Facts & Figures 2024' report, the United States is expected to surpass 2 million new cancer cases in a single year for the first time.

Download Free Sample Report

Key Market Challenges

The inconsistent insurance reimbursement policies within the healthcare sector constitute a substantial barrier hampering the growth of the Global Particle Therapy Market. While the clinical advantages of particle therapy are evident, the financial viability of operating these high-cost facilities is frequently undermined by uncertain payment models. Private insurers and government payers often categorize proton therapy as experimental for many indications or enforce strict prior authorization requirements, leading to frequent claim denials and payment delays. This unpredictability in revenue generation makes it difficult for medical institutions to recover the massive capital expenditures required for facility construction, thereby discouraging investors and stalling the development of new centers in emerging markets.

This challenging economic landscape is further intensified by downward pressure on established payment structures. According to the National Association for Proton Therapy, in 2024, the Centers for Medicare & Medicaid Services proposed a 1.5% payment rate decrease for codes mapping to Level 5 Radiation Therapy procedures. Such reductions in reimbursement rates for critical treatment codes directly impact the operational margins of existing facilities. Consequently, this financial volatility forces providers to limit patient intake or halt expansion plans, directly restricting the market's overall scalability and accessibility.

Key Market Trends

The Emergence of Ultra-High Dose FLASH Particle Therapy is transforming the market by enabling the delivery of radiation at ultra-high dose rates, typically in less than one second. This technological paradigm shift leverages the "FLASH effect" to significantly reduce toxicity to healthy tissues while maintaining rigorous tumor control, thereby addressing a critical limitation of conventional radiotherapy protocols. Research momentum in this domain is accelerating rapidly as leading medical institutions seek to translate preclinical success into clinical applications, attracting substantial funding for development. Illustrating this commitment to innovation, according to Penn Medicine, May 2024, in the 'FLASH forward to an ultra-fast new form of radiation' article, researchers secured a 12.3 million US dollar NIH grant to study proton FLASH therapy and its potential to spare normal tissue in cancer patients.

Simultaneously, the Widespread Adoption of Pencil Beam Scanning (PBS) Technology is becoming the industry standard, progressively replacing passive scattering methods to enhance treatment conformity. PBS enables Intensity-Modulated Proton Therapy (IMPT), allowing clinicians to "paint" tumors spot-by-spot with Bragg peak accuracy, which is essential for treating complex malignancies near critical structures. This technological dominance is increasingly reflected in major commercial contracts where PBS capabilities are a primary requirement for new facility installations. Evidencing this market preference, according to Imaging Technology News, May 2024, in the 'IBA signs contract with Yale New Haven Health and Hartford HealthCare to Install Proteus ONE Proton Therapy Solution' article, a contract valued between 40 and 50 million US dollars was signed for a system specifically equipped with Pencil Beam Scanning technology.

Segmental Insights

The breast cancer segment is projected to witness the fastest growth in the global particle therapy market due to the increasing adoption of proton therapy for minimizing long-term cardiac risks. Unlike conventional radiation, particle therapy provides precise dose delivery that significantly reduces unnecessary exposure to critical organs such as the heart and lungs, particularly for left-sided breast cancer. This clinical benefit is reinforced by ongoing clearances from regulatory bodies like the U.S. Food and Drug Administration, which improves accessibility. Consequently, rising disease prevalence drives the strong demand for this safer treatment option.

Regional Insights

North America maintains a leading position in the global particle therapy market due to established healthcare infrastructure and favorable reimbursement frameworks. The region benefits from a high concentration of operational proton therapy centers and substantial investments in oncology research. Support from regulatory bodies, such as the U.S. Food and Drug Administration, facilitates the timely approval and commercialization of therapeutic devices. Additionally, the presence of key manufacturers within the United States strengthens the supply chain and service delivery. These elements collectively drive the continuous adoption of particle therapy across the region.

Recent Developments

• In July 2025, Hitachi High-Tech Corporation received an order from the Tokyo Metropolitan Hospital Organization to install a proton therapy system at the Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital. The contract, signed in June 2025, outlined plans for a facility featuring one accelerator system and two rotating gantry treatment rooms. The project was awarded to a consortium including Takenaka Corporation and Hitachi High-Tech, with the latter responsible for the procurement and installation of the system. The new facility was scheduled to begin operations in fiscal year 2030, aiming to provide minimally invasive cancer treatment to patients in the Tokyo metropolis.
• In February 2025, Ion Beam Applications (IBA) signed a binding agreement with the Asian Institute of Gastroenterology (AIG) to supply a Proteus®ONE compact proton therapy system for a new oncology center in Hyderabad, India. This contract represented the first order for such a system in South Asia and the second private sector proton therapy center in the country. The agreement included a multi-year operation and maintenance package. The Chairman of AIG Hospitals stated that the acquisition was a transformative step in their mission to provide advanced cancer care, with patient treatments expected to commence in early 2028.
• In September 2024, Mevion Medical Systems announced a strategic partnership with Nebraska Medicine to integrate the MEVION S250-FIT Proton Therapy System into the Fred & Pamela Buffett Cancer Center in Omaha. This collaboration marked the second National Cancer Institute-designated center to adopt this specific compact technology. The system was designed to be installed in an existing radiation oncology vault, significantly reducing construction complexity and cost. The Chief Executive Officer of Mevion highlighted that this integration would enhance the accessibility and affordability of proton therapy for patients, supporting the health system's mission to provide advanced cancer care options in a single location.
• In April 2024, the National Institutes for Quantum Science and Technology (QST) in Japan announced the commencement of clinical treatments using a multi-ion heavy particle radiotherapy system developed in collaboration with Sumitomo Heavy Industries. This next-generation technology, often referred to as a "quantum scalpel," enabled the use of various ion beams—such as neon, oxygen, and helium—tailored to the specific malignancy of the tumor. The system was installed at the Heavy Ion Medical Accelerator in Chiba (HIMAC). This development marked a significant advancement from conventional heavy-ion therapy, which typically utilized only carbon ions, aiming to enhance treatment efficacy while minimizing side effects.

Key Market Players

• Advanced Oncotherapy plc
• Danfysik A/S
• Hitachi, Ltd
• IBA LLC
• Mevion Medical Systems, Inc.
• Optivus Proton Therapy, Inc.
• ProTom International, Inc.
• Provision Healthcare Ltd
• Sumitomo Heavy Industries, Ltd.
• Varian Medical Systems, Inc.

By Type	By System	By Application	By Cancer-type	By Region
Proton therapy Heavy-ion therapy	Multi-room systems Single-room systems	Treatment application Research application	Pediatric Cancer Lung Cancer Breast cancer Other cancers	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Particle Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Particle Therapy Market, By Type:

• Proton therapy
• Heavy-ion therapy

• Particle Therapy Market, By System:

• Multi-room systems
• Single-room systems

• Particle Therapy Market, By Application:

• Treatment application
• Research application

• Particle Therapy Market, By Cancer-type:

• Pediatric Cancer
• Lung Cancer
• Breast cancer
• Other cancers

• Particle Therapy Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE